Aberdeen Group
EWTX icon

Aberdeen Group’s Edgewise Therapeutics EWTX Stock Holding History

Aberdeen Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3M Sell
647,926
-178,133
-22% -$6.14M 0.04% 369
2026
Q1 		$26M Buy
826,059
+4,119
+0.5% +$119K 0.04% 341
2025
Q4 		$20.4M Buy
821,940
+202,062
+33% +$4.06M 0.03% 425
2025
Q3 		$10.1M Buy
619,878
+176,559
+40% +$2.5M 0.02% 603
2025
Q2 		$5.81M Buy
443,319
+130,294
+42% +$1.88M 0.01% 684
2025
Q1 		$6.89M Buy
313,025
+134,982
+76% +$3.54M 0.01% 641
2024
Q4 		$4.75M Sell
178,043
-78,602
-31% -$2.5M 0.01% 656
2024
Q3 		$6.85M Buy
+256,645
New +$5.11M 0.01% 596
2024
Q1 		– Sell
-150,418
Closed -$1.65M – 957
2023
Q4 		$1.65M Buy
+150,418
New +$1.06M ﹤0.01% 788

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Aberdeen Group's EWTX Position: Q2 2026 in Review

Aberdeen Group reduced its Edgewise Therapeutics (EWTX) stake by 22% in Q2 2026, selling an estimated $6.14M and leaving 647,926 shares worth $26.3M. The position accounts for 0.04% of the portfolio, ranked #369.

Aberdeen Group first reported a position in EWTX in Q4 2023 and has held it in 9 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Aberdeen Group held 647,926 shares of Edgewise Therapeutics worth $26.3M as of Q2 2026.
  • Aberdeen Group sold 178,133 Edgewise Therapeutics shares in Q2 2026, an estimated $6.14M.
  • Edgewise Therapeutics made up 0.04% of Aberdeen Group's portfolio in Q2 2026, its #369 holding.
  • Aberdeen Group first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.